• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Longeveron Inc. - Class A Common stock (NQ:LGVN)

    0.8849 -0.0423 (-4.56%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 9, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Longeveron Inc. - Class A Common stock

    < Previous 1 2 3 4 Next >
    Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
    From Longeveron
    Via GlobeNewswire
    Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
    From Longeveron
    Via GlobeNewswire
    InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present ‘Important’ Lomecel-B(TM) Data at the 17th Clinical Trials on Alzheimer’s Disease Conference
    Via Investor Brand Network
    BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Present at This Month’s Congenital Heart Surgeons’ Society Annual Meeting
    Via Investor Brand Network
    BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) CEO to Participate in Fireside Cat at UBS Virtual Organ Restoration and Cell Therapy Day
    Via Investor Brand Network
    BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Participate at the Cell & Gene Meeting on the Mesa
    Via Investor Brand Network
    BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Announces Alignment with FDA on Development Pathway for Lomecel-B(TM) in HLHS
    Via Investor Brand Network
    InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces Participation at H.C. Wainwright 26th Annual Global Investment Conference
    Via Investor Brand Network
    InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Reports on Q2 2024 Financial Results, Business Highlights
    Via Investor Brand Network
    BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Schedules Release of Q2 2024 Financial Results, Earnings Conference Call
    Via Investor Brand Network
    BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Lomecel-B(TM) Study Results Presented at the Alzheimer’s Association International Conference
    Via Investor Brand Network
    BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Closes on $9M Registered Direct Offering
    Via Investor Brand Network
    5 Stocks in the News to Watch Now: LGVN, PRSO, SIRI, INBS, VTAK
    Via AB Newswire
    InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Expands Growing Telecommunications Sector Through New Subsidiary
    Via Investor Brand Network
    InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Enters into $9M Registered Direct Offering
    Via Investor Brand Network
    InvestorNewsBreaks – Longeveron Inc.’s (NASDAQ: LGVN) Lomecel-B(TM) Granted Fast Track Designation for Treatment of Mild Alzheimer’s Disease
    Via Investor Brand Network
    TechMediaBreaks – Longeveron Inc.’s (NASDAQ: LGVN) Lomecel-B(TM) Granted RMAT Designation for the Treatment of Mild Alzheimer’s Disease
    Via Investor Brand Network
    BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Elected New Board Member at Annual Stockholder Meeting
    Via Investor Brand Network
    InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces Strategic Board Appointment of Gene Therapy Pioneer Roger Hajjar, MD
    Via Investor Brand Network
    InvestorNewsBreaks – Longeveron Inc.’s (NASDAQ: LGVN) Presentation at Virtual Life Sciences Investor Forum Made Available for Online Viewing
    Via Investor Brand Network
    Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    Life Sciences Virtual Investor Forum Agenda Announced for June 20th
    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Exercise Warrants for $4.4M, Present at Virtual Life Sciences Investor Forum
    Via Investor Brand Network
    Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
    EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Announces CEO Participation in Emerging Growth Conference, Completion of Investigator Meeting for Phase 2b Clinical Trial
    Via Investor Brand Network
    Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
    From FN Media Group LLC
    Via GlobeNewswire
    InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Participate in Upcoming Emerging Growth Virtual Conference
    Via Investor Brand Network
    BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Launches New Business, Eyes Opportunity in Contract Manufacturing
    Via Investor Brand Network
    InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Set to Participate in Upcoming BIO International Convention 2024
    Via Investor Brand Network
    BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Releases Financial Report, Business Update for Q1 2024
    Via Investor Brand Network
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.